Semaglutide and Menopause: Does It Still Work?

Why the Weight Equation Changes

The complaint that brings most women to this page is remarkably consistent. Nothing about the routine changed, but the body stopped responding to it. The eating that maintained a stable weight for twenty years now adds pounds. The pounds land somewhere new, around the middle instead of the hips. And the tools that used to fix it, a stricter month, more cardio, do less than they ever have. That experience is not imagined, and it is not a discipline problem. It has a documented biology.

The best data on what actually happens comes from the Study of Women’s Health Across the Nation, a longitudinal cohort that followed women through the transition with repeated DEXA body composition scans. Greendale and colleagues reported the pattern in 2019: at the start of the menopause transition, the rate of fat gain roughly doubled and lean mass began to decline, and both trajectories kept going until about two years after the final menstrual period before leveling off.

Greendale GA, Sternfeld B, Huang M, et al. "Changes in body composition and weight during the menopause transition." JCI Insight, 2019. PMID 30843880. View study

The same paper contains a detail almost nobody quotes, and it reframes the whole subject. Total body weight did not accelerate at the transition; it climbed at the same slow rate it had been climbing through the 40s. What menopause changes is the composition of the weight: faster fat gain and simultaneous muscle loss, roughly canceling on the scale while transforming what the scale is measuring. That is why clothes stop fitting at a number that used to be fine. Falling estrogen also shifts where fat is stored, away from the hips and toward the abdomen and the deeper visceral depot around the organs, which is the fat most closely tied to metabolic risk.

Two more pieces stack on top. Sleep fragments during the transition for many women, and short sleep reliably pushes appetite and food choices in the wrong direction, so the hormonal shift gets a behavioral amplifier. And the muscle that is quietly leaving was doing metabolic work: lean mass is a major driver of resting energy expenditure, so losing it lowers the daily calorie budget at exactly the moment fat gain speeds up. Add it together and the old weight equation genuinely no longer holds. More effort against a worse equation produces the "nothing works anymore" experience, and it deserves a better answer than trying harder.

Does Semaglutide Work After Menopause?

The short answer from the available evidence: yes, and to a comparable degree. Semaglutide works by mimicking GLP-1, a gut hormone that quiets appetite signaling in the brain and slows gastric emptying. None of that machinery depends on estrogen. The appetite circuits it acts on do not retire at menopause, so there was never a strong theoretical reason to expect the drug to stop working. What was missing until recently was data in this specific population, because the big trials of the approved products enrolled adults of all ages and sexes and did not report menopausal status.

That gap is starting to close. A 2025 cohort study by Nicolau and colleagues followed women treated with low-dose semaglutide, 1 mg weekly, for four months and compared postmenopausal women directly against premenopausal women. The postmenopausal group started heavier, with more fat mass. After four months, percentage of weight lost was statistically comparable between the groups, 5.8% versus 5.1%, and so were fat mass loss and lean mass loss measured by body composition analysis. A small study over a short window at a modest dose, but a direct comparison, and menopause did not blunt the response.

Nicolau J, Blanco-Anesto J, Bonet A, et al. "Effectiveness of Low Doses of Semaglutide on Weight Loss and Body Composition Among Women in Their Menopause." Metab Syndr Relat Disord, 2025. PMID 39761057. View study

The Mayo Clinic cohort covered in the next section points the same direction: the postmenopausal women in it who were not on hormone therapy still lost an average of 12% of body weight at 12 months, which sits in the range reported for semaglutide generally. So the honest summary is that menopause changes why weight is gained, but the cohort evidence so far says it does not switch off the medication that addresses it. The drug is working on appetite, and appetite is still where the leverage is.

One caution on expectations. If you search "semaglutide not working menopause," most of what you find is women three or four months in, still on a starting or middle dose, comparing themselves to a husband or a headline. Titration takes months by design, early doses are not the therapeutic dose, and week-to-week water shifts hide real fat loss. Menopause is rarely the explanation for a slow start; the dose schedule usually is.

The Hormone Therapy Finding

This is the part of the story that generic pages skip, and it is the most interesting data specific to this reader. A group at the Mayo Clinic, including researchers from its obesity and women’s health programs, ran a retrospective cohort study of 106 postmenopausal women treated with semaglutide for overweight or obesity. Sixteen were using menopausal hormone therapy; ninety were not. The women on hormone therapy lost more weight at every measured timepoint: 7% versus 5% at three months, 13% versus 9% at six, and 16% versus 12% at twelve. A larger share of them reached the 5% and 10% loss thresholds, and the association held after the authors adjusted for potential confounders.

Hurtado MD, Tama E, Fansa S, et al. "Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use." Menopause, 2024. PMID 38446869. View study

Now the honest framing. This was a retrospective look at charts, not a randomized trial, and only sixteen women were in the hormone therapy group. Women who take hormone therapy differ from women who do not in ways adjustment cannot fully capture: they tend to sleep better, and the groups in this study differed at baseline. The mechanism is plausible, since estrogen influences fat distribution and energy regulation, and the authors themselves called for larger studies rather than declaring the case closed. What the study supports is a modest, specific sentence: in one cohort, hormone therapy use was associated with a meaningfully better semaglutide response, roughly four percentage points more body weight lost at one year.

What it does not support is treating a GLP-1 prescription as a reason to start hormone therapy. HRT is its own medical decision with its own benefit and risk profile, made with a clinician who knows your history, your symptoms, and your cardiovascular and cancer risk picture. PeRx does not prescribe hormone therapy. If you are already on it, it belongs on your intake form so the prescriber sees the whole picture. If you are considering it, have that conversation with the clinician who manages your hormones, on its own merits, and let the weight data be a footnote rather than the reason.

The Muscle Stakes Are Higher Here

Every article about GLP-1s eventually mentions muscle. For a postmenopausal reader the topic is not a footnote, because she is starting the race from further back. Age-related muscle loss is already underway from the 30s onward, and the estrogen decline of the transition accelerates it: estradiol supports muscle maintenance and repair, and reviews of the sarcopenia literature identify the menopausal window as a period of raised vulnerability, with the SWAN data above showing lean mass actively declining through the transition itself.

Geraci A, Calvani R, Ferri E, et al. "Sarcopenia and Menopause: The Role of Estradiol." Front Endocrinol (Lausanne), 2021. PMID 34093446. View study

A GLP-1 then adds a substantial calorie deficit on top, and in body composition substudies of GLP-1 therapy a meaningful share of total weight lost is lean tissue. Context matters before that number scares anyone off: the fat-to-lean ratio resembles what is seen in other forms of weight loss, and a 2024 JAMA viewpoint by Conte, Hall, and Klein reviewed the evidence and argued the muscle-loss alarm is not supported by it, since lean losses are small relative to fat losses and physical function generally improves. Notably, the small Nicolau cohort above found postmenopausal women lost no more lean mass on semaglutide than premenopausal women did.

Conte C, Hall KD, Klein S. "Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?" JAMA, 2024. PMID 38829659. View study

So the reasonable position is not fear, it is margin. A woman starting semaglutide at 55 has less muscle in reserve than she did at 35, and the muscle she keeps through the loss determines how the after looks: resting metabolism, strength, steadiness, and how well the new weight holds once the scale stops moving. The two interventions with human evidence are the unglamorous ones. Protein on the order of 1 gram per pound of goal bodyweight, which takes deliberate effort when the medication has shrunk your appetite, and resistance training that loads the major muscle groups about three times a week. Loading muscle also loads the bone attached to it, which is not a small consideration in this decade.

The full breakdown of why GLP-1s cost lean mass and how to hold onto it, including where growth hormone axis peptides fit for someone who wants pharmacological support on top of the foundation, is in keeping muscle on a GLP-1 Read nextHow to Keep Muscle While Taking Ozempic, Wegovy, or MounjaroUp to 40% of weight lost on GLP-1 medications is lean muscle. Here is what the research actually shows, why it happens, and which growth hormone peptides providers prescribe to preserve lean mass during a caloric deficit.Read article . Read it as the companion to this page; everything in it applies here with the volume turned up.

What About Tirzepatide?

Everything on this page applies to tirzepatide as well. It is a dual agonist, acting on the GIP receptor alongside GLP-1, and in trials of the approved branded products it produced larger average weight loss than semaglutide did in its own trials. No study has yet examined tirzepatide response by menopausal status or hormone therapy use the way the Mayo group did for semaglutide, so the specific findings above are semaglutide findings. There is no reason to expect the direction to differ, and no data yet confirming it.

The distinction that has to stay clear on any page like this: Ozempic and Wegovy are FDA-approved semaglutide products, and Mounjaro and Zepbound are FDA-approved tirzepatide products, each approved on trials of those exact formulations. PeRx prescribes compounded semaglutide and compounded tirzepatide, prepared by a licensed pharmacy against an individual prescription. Compounded preparations have not been through FDA review, and the trial results in the literature belong to the approved products.

Where Peptides Honestly Fit

PeRx is a peptide clinic, so you would expect this section to be a sales pitch. Here is the honest version instead. No peptide treats menopause or any menopause symptom, and none should be bought on that promise. Hormone therapy questions belong with your own clinician, and the weight question is answered above by the GLP-1 itself. What peptides can do is address specific, adjacent goals that tend to travel with this stage of life, each with its own evidence tier, most of them thinner than the GLP-1 evidence base by a wide margin.

The two most defensible pairings for a woman on a GLP-1 are covered elsewhere on this site in detail. Growth hormone axis peptides such as CJC-1295/Ipamorelin Explore PeRxCJC-1295/IpamorelinPulsatile Growth Hormone ReleaseView peptide , used for body composition support during a deficit, are ranked against the alternatives in peptides to take with a GLP-1 Read nextPeptides to Take With a GLP-1: The EvidenceSearch this question and you get a stack. Every result recommends four or five peptides, none of them ranks the options, and none of them tells you which ones have human data behind them. This page sorts the same list into three tiers and says out loud which tier each one lands in.Read article . And GHK-Cu for skin after GLP-1 weight loss Read nextGHK-Cu for Skin After GLP-1 Weight LossThe honest version. Ozempic face is not something the drug did to your skin, it is what a face looks like when it loses fat quickly. That distinction decides which fixes are even in the right category. GHK-Cu has real evidence behind it for collagen and skin quality, and it has hard limits that nobody selling it likes to mention.Read article addresses the complaint that follows substantial weight loss at an age when collagen production was already declining: the deflation, the crepiness, the face that lost weight faster than it lost years.

For the transition symptoms themselves, sleep, joints, libido, and energy, the symptom-by-symptom map is in peptides for perimenopause symptoms Read nextPeptides for Perimenopause Symptoms: Sleep, Joints, and LibidoPerimenopause shows up as broken sleep, new joint aches, and a drop in desire, often all at once. Which peptides target each piece of the cluster, and where they fit alongside hormone therapy.Read article , and the broader ranked overview for this decade is best peptides for women over 40 Read nextBest Peptides for Women Over 40: What Actually WorksWhich peptides target the specific biological changes women face after 40: GH decline, body composition, skin quality, sleep, and recovery.Read article . Read all of it with the same skepticism this page has tried to model. The GLP-1 has trial evidence measured in tens of thousands of patients for the approved products. Most peptides are running on mechanism, animal data, and small human studies. That does not make them worthless; it makes them add-ons with a different burden of proof, to be judged one at a time against a specific goal you can actually measure.

Starting a GLP-1 in This Stage of Life

The intake form matters more at 55 than at 35, because the medication list is usually longer and some of it interacts with the decision. Things the prescriber genuinely needs to see: any hormone therapy, including patches, gels, and progesterone, since it is part of your metabolic picture even though PeRx does not manage it; thyroid medication, because dosing and monitoring context matters; anything for blood pressure, cholesterol, or blood sugar, since those numbers often move during weight loss and the prescriptions behind them may need attention from whoever manages them; and any history of gallbladder disease, pancreatitis, or medullary thyroid cancer in the family, which are the standard GLP-1 screening questions for everyone.

The process itself is simple. Your PeRx provider will prescribe an optimal protocol based on your intake, the medication arrives as a ready-to-use vial with syringes and an injection guide, and the dose is reviewed each 28-day cycle as the subscription renews. Injections are once weekly, subcutaneous, same day each week.

On pace: the double-digit percentages in the studies above are 12-month numbers, not 12-week numbers, and the early months are titration. A reasonable arc for this population, supported by the cohorts, is mid single digits by month four and low double digits by the one-year mark, with wide individual variation in both directions. The published figures also come from studies of specific products and doses; compounded preparations have not been through FDA review, so treat every number as an orientation, not a promise. Judge the medication at honest checkpoints, and bring a stall to the 28-day review rather than quietly concluding it failed.

Common Questions